Next-generation ‘anti-cancer weapons’ to be developed in innovative partnership between Randox and Transgene
Next-generation ‘anti-cancer weapons’ to be developed in innovative partnership between Randox and Transgene
Randox Laboratories has today announced an innovative European partnership with French biotech company Transgene, which aims to develop a game-changing therapy for cancer treatments.
It involves cutting-edge technology and ‘anti-cancer weapons’ in the form of oncolytic viruses which directly target and destroy the cancer cells, and also deliver antibodies in the tumour microenvironment to further attack the rest of the tumour. This has clear advantages over traditional treatments such as radiotherapy and chemotherapy which as well as targeting cancer cells, can affect healthy cells.
In addition, if successful, this therapy will address the efficacy challenges faced by either Oncolytic viruses or Check-point inhibitors’ neutralization used independently, as their combination is expected to trigger a sustained anti-tumoural immune response from the patient.
The partnership will bring together Randox’s unique collection of therapeutic single domain antibodies (sdABs), which are on the front line in the fight against cancer, and Transgene’s next-generation viral platform Invir.IO™.
Commenting on the agreement, Dr. Peter FitzGerald, Managing Director and Founder of Randox Laboratories, said:
“This collaboration will enable ground-breaking innovation and research to be carried out in a critical area of human health. The work we will be doing in the field of cancer treatment has an enormous potential benefit for patients through the delivery of more effective treatments. We are looking forward to working with Transgene to generate oncolytic viruses that will be able to deliver single and multiple payloads directly into the tumour, enhancing their efficacy. This partnership will allow us to better leverage our SdAb capabilities and immuno-oncology expertise, and add to our strategic collaborations across the world.”
Eric Quéméneur, PhD, Executive VP and VP Research & Development of Transgene, said:
“We are delighted to collaborate with Randox. Its library of SdAbs against major targets in immuno-oncology provides an excellent opportunity to demonstrate the high potential of our Invir.IO™ platform. We look forward to working with Randox and to generating novel product candidates which combine the merits of oncolytic virotherapy and local delivery of therapeutic payloads. We believe such targeted expression of therapeutic agents including immune checkpoint inhibitors will better potentiate the tumour microenvironment and paves the way for the development of a broad range of innovative cancer treatments.”
For further information about Randox’s collaboration with Transgene, please visit our Randox Biosciences website. Click here.
If you have any additional questions please contact Randox PR by phoning 028 9442 2413 or emailing RandoxPR@randox.com
Randox representing businesses in Donegal at Irish American Business Chamber and Network Event in Philadelphia
Randox Teoranta is joining a trade mission of Irish firms visiting Philadelphia this week for the Irish American Business Chamber and Network Symposium, in partnership with Údarás na Gaeltachta.
Alongside Complete Lab Solutions and Eirecomposites Teo from Galway, Westire Technology Teo from Mayo, and the National University of Ireland Galway, Randox Teoranta is taking part in Údarás na Gaeltachta’s third visit to the Irish Chamber, to showcase the business and job opportunities available in the Irish-speaking Gaeltacht.
The event was launched last night with a welcome reception in the prestigious Pyramid Club of Philadelphia, with a number of presentations, seminars and networking opportunities taking place during today’s session at The Union League of Philadelphia.
Senior Manager of Randox Laboratories, Mark Campbell, who is attending the Symposium in Philadelphia, is looking forward to showcasing what Donegal has to offer, meeting potential business partners and finding new investment opportunities;
“It is a great honour and privilege to join Údarás na Gaeltachta on their Trade Mission and to represent businesses within Donegal at the Symposium. Not only do we have key diagnostics capabilities of interest to the US, we also want to let the wider Irish diaspora know that there are world-leading career opportunities on offer in Donegal, including those in the life sciences, engineering and software development industries. Our revolutionary diagnostics simultaneously allow us to partner with like-minded innovators in markets overseas, and to create further employment at home.”
In 2015 Randox Teoranta in Donegal announced an investment of €25 million to extend and develop the R&D and manufacturing facilities of the state-of-the-art biotech facility. The investment in the site will accelerate the development of new products into a wide range of clinical needs, including various cancers, stroke, heart disease and neurodegenerative disorders.
Mark continued;
“Interest in Donegal as an exciting place to live and work has grown significantly in recent times. In the past year alone Donegal Airport was voted one of the world’s most scenic airports, and the National Geographic Traveller named Donegal the coolest place on the planet.
“Our Randox site in Dungloe has much to offer the US and we are looking forward to sharing our innovative diagnostic technologies and our world-class careers with the members of the Irish American Business Chamber and Network.”
Mícheál Ó hÉanaigh, Director of Enterprise, Employment and Property, Údarás na Gaeltachta, is heading up the delegation to Philadelphia, and commented;
“Údarás na Gaeltachta are delighted to have the opportunity to showcase all of our Gaeltacht areas at the Irish American Business Chamber and Network Symposium. Our Diaspora are an essential element in attracting business and employment home to Ireland and to our Gaeltacht areas, a lot of which are located in remote and peripheral areas. We are very proud to be able share a platform with and showcase a cross section of our excellent client companies such as Randox who reflect the business success that can be achieved in cooperation with Údarás na Gaeltachta.”
For more information about the American Business Chamber and Network Symposium please contact Randox PR on 028 9445 1016 or email RandoxPR@randox.com
Randox Biosciences and Dana-Farber Cancer Institute Celebrate Success of Transatlantic Partnership
Today, Randox Biosciences and Dana Farber Cancer Institute highlighted the milestones achieved during their joint partnership. The collaborative partnership was the focus of the Boston-Ireland Precision Medicine Seminar with partners the City of Boston and the Massachusetts Life Science Center (MLSC).
The City of Boston Office of Economic Development and the Massachusetts Life Science Center are collaborating with Randox Biosciences on an innovative event to discuss the Boston-Ireland linkage in the field of Precision Medicine. The event will build business and science relationships between leading life science organizations. The program will highlight Boston as a global life science hub and illustrate why global leaders like Randox are seeking to build business partnerships in the area.
“Dana-Farber is a world-renowned name in the field of oncology and it is great to be working on this exciting new technology which is being developed in the lab of Dr. Novina.” Marshall Dunlop of Randox Laboratories said.
In the last year, the clinical diagnostics and life sciences provider Randox Laboratories has established a collaborative agreement with Dr. Carl Novina at the Dana-Farber Cancer Institute and Harvard Medical School. The goal of this collaboration is to develop therapeutic antibodies that will be incorporated into a platform technology that can reprogram patients’ immune systems to attack cancers.
“I am excited to work with Randox and use these important antibody technologies to help develop a novel cancer therapy that could potentially make a real difference for cancer patients.” said Dr. Carl Novina, Dana Farber Cancer Institute.
The Randox BioSciences and Dana Farber relationship highlights the close ties between Boston, Massachusetts and Ireland and provides another example of the strengths of Boston and Ireland in the life sciences sector. The life sciences industry continues to thrive all across Boston, from Longwood Medical Area – a world-famous medical campus with over 43,000 scientists, researchers, and staff including over 19,000 students – to the South Boston Waterfront District, the city’s newest cluster of high tech research, development, and manufacturing firms.
The City of Boston Chief of Economic Development John Barros said, “Mayor Martin J. Walsh is proud of Boston’s historic links with Ireland and the diverse economic bridges these links have created today. Within the life sciences alone, our researchers and businesses work together in new ways every day to shape how we treat, cure, and innovate together. By partnering with Randox and other leaders in the field, we continue to tackle global challenges together. Here at the City of Boston, we are committed to maintaining open doors as a global and welcoming city. These international partnerships will continue to play an active role in fostering opportunities for collaboration and growth.”
“Collaboration is the key ingredient that makes Massachusetts the best place in the world to innovate,” said Travis McCready, President & CEO of the MLSC. “It is great to see Randox collaborating with the leading scientists at the Dana-Farber Cancer Institute, toward the development of improved, targeted treatments for cancer patients.”
For more information about the Precision Medicine Seminar in Boston please contact Randox PR on 028 9445 1016 or email RandoxPR@randox.com
